Rx Cost-Saving Potential In Medicare Not Yet Demonstrated, CBO Says

Congressional Budget Office cost estimates for Medicare prescription drug proposals will continue to leave out any estimate of cost savings from expanded use of pharmaceuticals, CBO Director Douglas Holtz-Eakin suggested during an April 9 House Ways & Means Committee hearing